AbbVie, Harbour BioMed, Utrecht University & Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody The...
05 Juni 2020 - 12:00PM
Business Wire
AbbVie (NYSE:ABBV), Harbour BioMed (HBM), Utrecht University
(UU) and Erasmus Medical Center (EMC) today announced they have
entered into a collaboration to develop a novel antibody
therapeutic to prevent and treat COVID-19, the pandemic respiratory
disease caused by the SARS-CoV-2 virus. The focus of the
collaboration is on advancing the fully human, neutralizing
antibody 47D11 discovered by UU, EMC and HBM and recently reported
in Nature Communications. This antibody targets the conserved
domain of the spike protein of SARS-CoV-2.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200605005064/en/
Under the terms of the collaboration, AbbVie will support UU,
EMC and HBM through the preclinical activities, while
simultaneously undertaking preparations for later stage preclinical
and clinical development work. AbbVie will receive an option to
exclusively license the antibody from the three parties for
therapeutic clinical development and commercialization
worldwide.
“Treatment and prevention of COVID-19 remains a critical global
need. The antibody discovered by UU, EMC and Harbour BioMed is
extremely promising based on the mechanism by which it targets the
virus and on its developability as a fully human protein,” said Tom
Hudson, M.D., Senior Vice President, Research and Development and
Chief Scientific Officer, AbbVie. “We look forward to working with
this outstanding team to advance this antibody towards clinical
trials.”
“AbbVie is a global leader in developing innovative antiviral
therapies,” said Dr. Jingsong Wang, Founder, Chairman & Chief
Executive Officer of HBM. “This collaboration will greatly
accelerate our efforts to bring this antibody forward into clinical
trials as quickly as possible and contribute a solution to this
pandemic.”
“The SARS-CoV-2 pandemic has highlighted the importance of
understanding coronavirus biology,” said Berend-Jan Bosch, PhD,
Associate Professor, Research leader at UU. “The collaboration with
AbbVie provides an excellent opportunity to translate our research
into a clinical candidate with great potential for advancing the
fight against this disease.”
Frank Grosveld, PhD, Academy Professor of Cell Biology, EMC,
Rotterdam and Founding Chief Scientific Officer at Harbour BioMed,
commented, “The collaboration is an endorsement of our approach to
fully human antibody discovery and development. Through this
collaboration, we are well positioned to move rapidly towards
clinical trials.”
The antibody discovery, published online on May 4 in Nature
Communications, targets a conserved region of the virus’ spike
protein. In cell culture studies the antibody blocked infection by
the SARS-CoV-2 and a second coronavirus SARS-CoV. The antibody is
fully human, which is designed to facilitate its development and
minimize immune-related side effects.
About AbbVie AbbVie’s mission is to discover and deliver
innovative medicines that solve serious health issues today and
address the medical challenges of tomorrow. We strive to have a
remarkable impact on people’s lives across several key therapeutic
areas: immunology, oncology, neuroscience, eye care, virology,
women’s health and gastroenterology, in addition to products and
services across its Allergan Aesthetics portfolio. For more
information about AbbVie, please visit us at www.abbvie.com. Follow
@abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About Utrecht University Founded in 1636, Utrecht
University is one of the largest research universities of Europe,
with over thirty thousand students and a staff of more than six
thousand. We invest in creating the leaders of the future through
innovative education of the highest quality, as reflected by the
University's consistently high position in international rankings.
Dedicated to performing groundbreaking research aimed at resolving
large global issues, our culture of cooperation is a breeding
ground for innovation, new insights and social impact.
www.uu.nl.
About Erasmus Medical Center Erasmus MC is the largest
University Medical Center in the Netherlands. Our primary goal is a
healthy population. Nearly 14,000 employees devote themselves every
day to providing outstanding care, facilitating world-class
education and conducting pioneering research. These professionals
are instrumental in developing expertise on health and illness.
They link the latest scientific insights to practical treatments
and prevention measures to provide maximum benefit to patients and
to enable healthy people to stay healthy longer. Being visibly
better and leading the way in the areas of complex, innovative and
acute care by collaborating with others: these are key ambitions at
Erasmus MC.
About Harbour BioMed Harbour BioMed is a global, clinical
stage biopharmaceutical company developing innovative therapeutics
in the fields of immuno-oncology and inflammatory diseases. The
company is building its proprietary pipeline through internal
R&D programs, collaborations with co-discovery and
co-development partners and select acquisitions. The company's
internal discovery programs are centered around its two patented
transgenic mouse platforms (Harbour Mice®) for generating both
fully human monoclonal antibodies and heavy chain only antibodies
(HCAb) and HBICE™ immune cell engager technology for developing
bispecific antibodies. Harbour BioMed also licenses the platforms
to companies and academic institutions. The company has operations
in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Suzhou
& Shanghai, China. For more information, please visit
www.harbourbiomed.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200605005064/en/
Media Contacts:
AbbVie Adelle Infante Phone: 847-938-8745 E-mail:
adelle.infante@abbvie.com
Harbour BioMed Atul Deshpande PhD, MBA Chief Strategy
Officer and Head, US Ops. Phone: +1-908-210-3347 E-mail:
atul.deshpande@harbourbiomed.com
Erasmus MC David Drexhage Press Officer Phone: 31 10 703
55 25 E-mail: d.drexhage@erasmusmc.nl
Utrecht University Myrna Tinbergen, Press Officer Phone:
+31 6 48 43 47 84 E-mail: m.j.tinbergen@uu.nl
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
Von Mär 2023 bis Mär 2024